Freemantle, NickNickFreemantleMollon, PatrickPatrickMollonMeyer, TimTimMeyerANN-LII CHENGEl-Khoueiry, Anthony BAnthony BEl-KhoueiryKelley, Robin KRobin KKelleyBaron, Ari DAri DBaronBenzaghou, FawziFawziBenzaghouMangeshkar, MilanMilanMangeshkarAbou-Alfa, Ghassan KGhassan KAbou-Alfa2023-01-122023-01-122022-060959-8049https://scholars.lib.ntu.edu.tw/handle/123456789/627199The CELESTIAL trial (NCT01908426) demonstrated overall survival benefit for cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (aHCC) who had received prior sorafenib treatment. This analysis of CELESTIAL compared the impact of cabozantinib versus placebo on health-related quality of life (HRQoL).enCabozantinib; Carcinoma; Hepatocellular; Liver neoplasms; Patient Reported Outcome Measures; Patient health questionnaire; Quality-adjusted life years; Visual analog scale[SDGs]SDG3journal article10.1016/j.ejca.2022.03.021354871832-s2.0-85130634051WOS:000819787600012https://api.elsevier.com/content/abstract/scopus_id/85130634051